Stoke Therapeutics, Inc.
STOK
Positions held
Your positionsSTOK isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Stoke Therapeutics is positioned in the biotechnology industry, focusing on innovative therapies that address unmet medical needs, which can attract significant investor interest.
- Revenue increased by 50% compared to the prior quarter, reaching $9.3 million.
- The operating margin improved to -701.7%, indicating potential for future operational efficiencies.
- The company is currently facing challenges with a negative profit margin and significant operating losses, which raises concerns about its financial health.
- Stoke's revenue growth has been declining, with a yearly revenue of only $8.78 million in 2023.
- The stock has a strong sell signal with a score of -24.00, indicating bearish market sentiment.
Fundamentals
| Market cap | $1.55B | Enterprise value | $1.26B | Trailing P/E | — | Forward P/E | -6.81 |
| PEG | — | Price / book | 4.33 | Beta | 1.26 | Dividend yield | 0.00% |
| Revenue growth | -32.5% | Earnings growth | — | Gross margin | 100.0% | Operating margin | -7.0% |
| Profit margin | 0.0% | ROE | -61.1% | ROA | -35.9% | Debt / equity | 0.01 |
| Current ratio | 7.69 | Free cash flow | -$106.20M | Analyst recommendation | strong_buy | Mean target | $46.46 |
| 52w high | $40.22 | 52w low | $20.32 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $9.3M | $6.2M | $1.4M | $10.6M | $13.8M | — |
| Op margin | -701.7% | -857.6% | -4382.2% | -405.3% | -197.6% | — |
| Net income | -$61.6M | -$50.0M | -$57.9M | -$38.3M | -$23.5M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$65.4M | -$53.4M | -$61.4M | -$43.1M | -$27.3M | — |
- Revenue +50% vs prior quarter ($9.3M vs $6.2M).
- Operating margin expanded to -701.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $184M | $36.6M | $8.8M | $12.4M | — |
| Op margin | -11.2% | -277.3% | -1307.2% | -841.2% | — |
| Net income | -$6.9M | -$89.0M | -$105M | -$101M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$20.6M | -$101M | -$115M | -$104M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · Stoke Therapeutics Completes FDA Meeting on Planned Zorevunersen NDA
2026-09-16 · Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-09-02 · Stoke Therapeutics to Present at the Cantor Global Healthcare Conference
2026-08-21 · Stoke Therapeutics shares rise as JPMorgan starts coverage with Overweight rating
2026-08-18 · Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Price (daily)
Full chart · RSI · MACD · patterns